EVIPLERA (tenofovir disoproxil
fumarate/emtricitabine/
rilpivirine), is now available on the
Pharmaceutical Benefits Scheme.
The medication is a complete
once-daily single tablet regimen
indicated for the treatment of HIV
infection in antiretroviral
treatment-naïve adults with plasma
HIV-1 RNA < 100,000 copies/mL at
the start of therapy.
The drug combines Truvada and
Janssen’s rilpivirine 25mg.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 29 May 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
